CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Tolcapone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02949934
NCT02949934Phase 2Completed
CompareCT.gov

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Medical University of South Carolina·interventional·Posted Oct 31, 2016·Updated Jun 9, 2023

In Brief

A Phase 2 clinical trial evaluating Tolcapone and Placebo for Alcohol Use Disorder. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation associated with cognitive control as a function of a participant's genotype at a polymorphism in the COMT gene.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 31, 2016
Enrollment StartMay 1, 2016
Primary CompletionApr 13, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.7 years ago

Interventions

Tolcaponedrug

Placebodrug